Parkinson's disease is associated with clonal hematopoiesis with TET2 mutation.
Kyung Ah WooHan-Joon KimChan Young LeeJung Hwan ShinChoonghyun SunHogune ImHongyul AnJiwoo LimSu-Yeon ChoiYoungil KohBeomseok JeonPublished in: NPJ Parkinson's disease (2024)
Clonal hematopoiesis of indeterminate potential (CHIP), a premalignant expansion of mutated hematopoietic stem cells, is linked to immune alterations. Given the role of neuroinflammation and immune dysfunction in Parkinson's disease (PD), we hypothesized a connection between CHIP and PD. We analyzed peripheral blood DNA from 341 PD, 92 isolated REM sleep behavior disorder (iRBD) patients, and 5003 controls using targeted sequencing of 24 genes associated with hematologic neoplasms. PD cases were classified by clinical progression mode: fast, slow, and typical. Using multivariable logistic regression models, CHIP prevalence was assessed against controls with a 1.0% variant allele fraction threshold. CHIP with TET2 mutations was more prevalent in PD than controls (aOR 1.75, 95% CI 1.11-2.77, p = 0.017), particularly in the fast motor progression subgroup (aOR 3.19, p = 0.004). No distinct associations were observed with iRBD. PD is linked to increased odds of CHIP with TET2 mutations, suggesting immune dysregulation in PD pathophysiology.
Keyphrases
- high throughput
- stem cells
- circulating tumor cells
- peripheral blood
- newly diagnosed
- physical activity
- ejection fraction
- oxidative stress
- traumatic brain injury
- risk assessment
- circulating tumor
- single cell
- randomized controlled trial
- brain injury
- prognostic factors
- depressive symptoms
- cell free
- human health
- nucleic acid